Remove Cardiology Remove Clinical Research Remove Life Science
article thumbnail

Obicetrapib Lowers LDL-C as Monotherapy and with Ezetimibe in Phase III Trials

XTalks

XTALKS WEBINAR: How Quality Management Drives Continuous Improvement for Life Sciences Organizations Live and On-Demand: Wednesday, February 19, 2025, at 10am EST (3pm GMT/UK) Register for this free webinar to learn about the shifting regulatory expectations surrounding quality and examine the latest trends shaping the life sciences sector.

Trials 52
article thumbnail

Lilly’s Lepodisiran Achieves Over 90% Reduction in Heart Disease Marker in Phase II Trial

XTalks

The Phase II results were presented at the American College of Cardiology 2025 Scientific Sessions. Ruth Gimeno, Eli Lillys vice president of Diabetes, Obesity and Cardiometabolic Research, emphasized the potential of lepodisiran to provide long-term benefits with infrequent dosing.

Trials 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Introducing the new NIHR National Patient Recruitment Centres

pharmaphorum

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. Yan Yiannkou is a consultant gastroenterologist and Clinical Director of the NIHR Patient Recruitment Centre (Newcastle).

article thumbnail

Introducing the new NHS Patient Recruitment Centres

pharmaphorum

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. Yan Yiannkou is a consultant gastroenterologist and Clinical Director of the NIHR Patient Recruitment Centre (Newcastle).

article thumbnail

Cardiovascular Clinical Trials with Patient Diversity: Challenges and Considerations

XTalks

Enrollment will be slower, and efficiency will not be what was expected,” says Dr. Satya Shreenivas, MD, Medical Director from the global clinical research organization (CRO) Medpace. Why Should We Care About Diversity and Equity in Clinical Research? In the same webinar, Dr. Hansie M.

article thumbnail

Cardiac Biomarkers in Cardiovascular Clinical Trials: Caveats and Considerations

XTalks

This is a part of the precision cardiology approach and could lead to their use as prognostic indicators. The Double-Edged Sword of Cardiac Biomarkers. Therefore, to complement biomarkers, inclusion of additional safety procedures such as imaging, vital signs, safety labs and ECGs will support safety and risk mitigation needs, Moore says.

article thumbnail

Heart and Kidney Health for All: Expanding Cardiovascular Clinical Trials to Include CKD Patients

XTalks

Srivastava recently spoke on a webinar where he shared insights on the imperative need to bridge this research gap and include more CKD patients in cardiovascular clinical trials. Vice President of the Medical Department and Cardiology therapeutic lead, and Heather Lohr, Sr. Director of Clinical Trial Management.